Study questions hepatitis C drug’s effectiveness.
The Cochrane Collaboration, an independent global network of researchers, assessed trials of breakthrough hepatitis C treatments and discovered that expensive direct-acting anti-viral drugs (DAAs) may be ineffective against the disease.
“The lack of valid evidence and the possibility of potentially harming people with chronic hepatitis ought to be considered before treating people with hepatitis C with DAAs,” the report concludes.
Read full article: No valid evidence $40,000 miracle drug cures hepatitis C – study — RT Viral
|Read Full Article: No valid evidence $40,000 miracle drug cures hepatitis C – study — RT Viral|